Naveen Pemmaraju, a medical doctor at The University of Texas MD Anderson Cancer Center, joins the discussion on unmet treatment needs in myelofibrosis (MF). They explore the complexities of managing prefibrotic MF and the challenges of thrombocytopenia. Insights into novel therapies like megakaryocyte-focused treatments and the importance of early intervention are highlighted. The conversation emphasizes patient participation in choosing therapies and the potential of innovative approaches like immune vaccines to improve outcomes.

Hematologist Naveen Pemmaraju discusses BPDCN treatment, focusing on CD123-targeting agents like Tagraxofusp. The guests emphasize the importance of early diagnosis, CNS involvement, and tailored strategies for treating adolescents and young adults with this aggressive disease.

Guest Naveen Pemmaraju, MD, talks about the challenges and novel agents being explored in BPDCN. The podcast discusses the BPD-CN international registry, advancements in diagnosis and treatment, and the importance of multidisciplinary teams and improved communication.